Could I Have Been Completely Wrong About CVS?

I have already asked in a previous article , if I am wrong about CVS Health Corporation (NYSE: CVS ). The article was published in January 2023 and in the article, I wrote the following conclusion:My analysis is focused on high-quality companies, that can outperform the market over the long-run due to a competitive advantage (economic moat) and high levels of defensibility. Focused on European and North American companies, but without constraints regarding market capitalization (from large cap to small cap ...